Masataka Sato

Masataka Sato

Auto-generated profile, based on publicly available information

Masataka Sato

Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
PSParmanand Sharma
Parmanand Sharma
NTNaoki Takahashi
Naoki Takahashi
TNTakahiro Ninomiya
Takahiro Ninomiya
MSMasataka Sato
Masataka Sato
TMTakehiro Miya
Takehiro Miya
TNToru Nakazawa
Toru Nakazawa
Glaucoma, a leading cause of blindness, requires accurate early detection. We present an AI-based Glaucoma Screening (AI-GS) network comprising six lightweight deep learning models (total size: 110 MB) that analyze fundus images to identify early structural signs such as optic disc cupping, hemorrhages, and nerve fiber layer defects. The segmentation of the optic cup and disc closely matches that of expert ophthalmologists. AI-GS achieved a sensitivity of 0.9352 (95% CI 0.9277–0.9435) at 95% specificity. In real-world testing, sensitivity dropped to 0.5652 (95% CI 0.5218–0.6058) at ~0.9376 specificity (95% CI 0.9174–0.9562) for the standalone binary glaucoma classification model, whereas the full AI-GS network maintained higher sensitivity (0.8053, 95% CI 0.7704–0.8382) with good specificity (0.9112, 95% CI 0.8887–0.9356). The sub-models in AI-GS, with enhanced capabilities in detecting early glaucoma-related structural changes, drive these improvements. With low computational demands and tunable detection parameters, AI-GS promises widespread glaucoma screening, portable device integration, and improved understanding of disease progression.

14 June 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
AHAkiko Hanyuda
Akiko Hanyuda
STSatoru Tsuda
Satoru Tsuda
NTNaoki Takahashi
Naoki Takahashi
MSMasataka Sato
Masataka Sato
KSKota Sato
Kota Sato
TNToru Nakazawa
Toru Nakazawa
Glaucoma is the leading cause of irreversible blindness worldwide and is characterized by progressive retinal ganglion cell (RGC) loss and optic nerve degeneration. While elevated intraocular pressure (IOP) remains the primary modifiable risk factor, a certain proportion of patients continue to deteriorate despite adequate IOP control, pointing to IOP-independent mechanisms of neurodegeneration. Oxidative stress—defined as an imbalance between the production of reactive oxygen species and the capacity of endogenous antioxidant defenses—has emerged as a central, multi-tiered contributor to glaucoma pathogenesis. In the anterior segment, chronic oxidative damage to the trabecular meshwork impairs aqueous humor outflow and drives IOP elevation. In addition, oxidative stress may impair ocular biomechanical integrity, including corneal hysteresis and lamina cribrosa, resulting in heightened susceptibility to IOP fluctuations. In the posterior segment, oxidative stress directly contributes to mitochondrial damage and vascular endothelial injury, leading to RGC apoptosis. The nuclear factor erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) pathway coordinates the principal endogenous antioxidant response, while nicotinamide adenine dinucleotide (NAD+) depletion links redox imbalance to metabolic vulnerability of RGCs. This narrative review synthesizes evidence published up to March 2026 on the molecular mechanisms of oxidative stress in glaucoma, the role of biomarkers in aqueous humor and systemic circulation, and the translational landscape of antioxidant-based neuroprotection—including nicotinamide, coenzyme Q10, alpha-lipoic acid, and Nrf2-activating compounds. We highlight gaps between preclinical promise and clinical evidence, and outline priorities for future randomized controlled trials.

17 July 2024 in Ophthalmology
Verified
Journal Article
Closed access
MAMasato Akiyama
Masato Akiyama
GTGen Tamiya
Gen Tamiya
KFKohta Fujiwara
Kohta Fujiwara
YSYukihiro Shiga
Yukihiro Shiga
YYYu Yokoyama
Yu Yokoyama
KNKoji M. Nishiguchi
Koji M. Nishiguchi

29 March 2024 in Ophthalmology Glaucoma
Verified
Journal Article
Open access
MSMasataka Sato
Masataka Sato
NKNaoki Kiyota
Naoki Kiyota
TYTakeshi Yabana
Takeshi Yabana
SMShigeto Maekawa
Shigeto Maekawa
STSatoru Tsuda
Satoru Tsuda
TNToru Nakazawa
Toru Nakazawa
To investigate sectoral differences in the relationship between intraocular pressure (IOP) dynamics during dark-room prone testing (DRPT) and visual field (VF) defect progression in primary open-angle glaucoma (POAG) patients. Retrospective, longitudinal study PARTICIPANTS: This retrospective study included 116 eyes of 84 POAG patients who underwent DRPT and had at least five reliable VF tests conducted over a more than two-year follow-up period. We excluded eyes with mean deviation worse than -20 dB or a history of intraocular surgery or laser treatment. Average total deviation (TD) was calculated in the superior, central, and inferior sectors of the Humphrey 24-2 or 30-2 program. During DRPT, IOP was measured in the sitting position, and after 60 minutes in the prone position in a dark room, IOP was measured again. The relationship between IOP change during DRPT, IOP after DRPT, and TD slope in each quadrant was analyzed with a linear mixed-effects model, adjusting for other potential confounding factors. TD slope in each quadrant, IOP change during DRPT, and IOP after DRPT RESULTS: IOP after DRPT and IOP change during DRPT were 18.16±3.42 mmHg and 4.92±3.12 mmHg, respectively. Superior TD slope was significantly associated with both IOP after DRPT (β=-0.28, p=0.003) and IOP change during DRPT (β=-0.21, p=0.029), while central (β=-0.05, p=0.595; β=-0.05; p=0.622) and inferior (β=0.05, p=0.611; β=0.01, p=0.938) TD slopes were not. DRPT might be a useful test to predict the risk of superior VF defect progression in eyes with POAG.